Schrödinger To Present New Data For SGR-1505 And SGR-2921 At American Society Of Hematology 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Schrödinger (NASDAQ:SDGR) announced that new data on its investigational drugs SGR-1505 and SGR-2921 will be presented at the American Society of Hematology (ASH) 65th Annual Meeting. The data supports the continued development of SGR-1505 as a potential therapy for patients with advanced B-cell malignancies. SGR-2921 has shown strong anti-leukemic activity in preclinical models of acute myeloid leukemia (AML). The company will review these data as part of its Pipeline Day on December 14, 2023.
November 02, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Schrödinger's announcement of new data on its investigational drugs SGR-1505 and SGR-2921 could potentially boost investor confidence in the company's pipeline. The data supports the continued development of these drugs as potential therapies for B-cell malignancies and AML.
The announcement of new data on Schrödinger's investigational drugs SGR-1505 and SGR-2921, which supports their potential as therapies for B-cell malignancies and AML, could potentially boost investor confidence in the company's pipeline. This could lead to increased demand for the company's stock, potentially driving its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100